As curative cell and gene therapies become increasingly effective, discovering payment strategies to help patients pay for the life-saving treatments is an imperative undertaking, Novartis CEO Vas Narasimham writes in a recent commentary published on CNBC.
“We now have within our grasp medicines that can reverse congenital blindness, potentially cure some cancers and save children from certain death from genetic neurological conditions,” he writes.
Narasimham notes that the current health care system generally pays for medicines over time due to the “chronic nature of the diseases these medicines treat.”
“Cell and gene therapies, however, are mostly one-time treatments,” he writes. “They are developed, manufactured, distributed and administered in fundamentally different ways from the medicines that preceded them, and we therefore need a new model that can support their continued development and ensure access for patients.”